Laureate Begins Production of Second Patrys Antibody

Patrys Ltd. has extended its relationship with Laureate Biopharmaceutical Services, Inc., to manufacture its lead product PAT-LM1 for preclinical and clinical use. PAT-LM1 is a human antibody that has been shown to have anti-cancer properties in animal models, including pancreatic, lung and colon cancers.

Patrys has an existing arrangement with Laureate for the production of another anti-cancer product PAT-SM6, which is currently being evaluated in a clinical trial in patients with melanoma.

“Laureate has extensive antibody production experience and given the success with PAT-SM6 production, which is very similar to what will be needed for PAT-LM1, Patrys is confident that Laureate can produce yields of PAT-LM1 sufficient to support commercialization,” said Mike Conner, Patrys vice president, manufacturing.

Michael A. Griffith, chief executive officer of Laureate, said, “We are pleased to be Patrys’ chosen manufacturing partner, giving Laureate the opportunity to share in the advancement of their novel anti-cancer products through clinical development.”